Last reviewed · How we verify
NPL insulin
NPL insulin is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage in peripheral tissues.
NPL insulin is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | NPL insulin |
|---|---|
| Sponsor | University of Campania Luigi Vanvitelli |
| Drug class | Insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
NPL (Neutral Protamine Lispro) insulin is an intermediate-acting insulin formulation combining rapid-acting insulin lispro with protamine to extend its duration of action. It mimics endogenous basal insulin secretion by activating insulin receptors on muscle, adipose, and hepatic cells, thereby lowering blood glucose levels through increased glucose utilization and reduced hepatic glucose production.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes (PHASE3)
- Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE) (PHASE3)
- Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY) (PHASE3)
- A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial (PHASE1)
- Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPL insulin CI brief — competitive landscape report
- NPL insulin updates RSS · CI watch RSS
- University of Campania Luigi Vanvitelli portfolio CI